Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Open accessThe DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
Background: The number of obese people continues to increase worldwide, and obesity-related complications add to every country's health burden. Consequently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), are attracting increasing attention. This study sought to assess the cost effectiveness for weight loss of 4 GLP-1RAs in adult patients with obesity in the United States. Methods: Four GLP-1RA groups that received Liraglutide (1.8 mg QD), Semaglutide (1.0 mg QW), Dulaglutide (1.5 mg QW), or Exenatide (10 μg BID), and one no-treatment group were compared using a decision-tree model. All the estimated parameters were derived from published articles. Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) were adopted as the study endpoints. We analyzed the results with the willingness-to-pay (WTP) threshold, and conducted deterministic and probabilistic sensitivity analyses. Results: The GLP-1RAs produced effective weight-loss results; however, not all the GLP-1RAs were cost effective compared to no treatment based on a WTP threshold of $195000/QALY. Among the 4 GLP-1RAs, Semaglutide provided a cost-effective strategy with an ICER of $135467/QALY. The sensitivity analyses showed that these results are reliable. Conclusions: Among the 4 GLP-1RAs, Semaglutide was the most cost-effective obesity medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In short term analyses (∼1/2 year) evaluating quality adjusted life years (QALYs) and incremental cost effectiveness ratios (ICERs), semaglutide was the most cost-effective compared to exenatide, dulaglutide, liraglutide or no treatment82 (Fig. 2).”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [82]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432 · cited 1×
“Conversely, pharmacotherapy is a non-invasive approach that can help people with obesity to adhere to weight-loss strategies, improve their quality of life, and reduce the risk of comorbidities (6).”
BackgroundThe Public Health Impact of Obesity
Visscher, T. L., & Seidell, J. C. (2001) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.22.1.355 · Cited by 1,008 · cited 1×
“A 5% weight loss in obese patients can improve their health and reduce the incidence of obesity-related complications (4).”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Glucagonlike peptide-1 receptor agonists (GLP-1RAs) are a class of therapeutic agents that provide significant improvements in Hemoglobin A1c (HbA1c), and also promote weight loss and carry a low risk of hypoglycemia (7-9).”
Backgroundon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
The Global Burden of Obesity and the Challenges of Prevention
Seidell, J. C., & Halberstadt, J. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000375143 · Cited by 786 · cited 1×
“An estimated 650 million adults are overweight or obese, and the number of obese people continues to increase worldwide (1).”
BackgroundPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · cited 1×
“Additionally, Semaglutide is currently available in oral formulation, and the effect and price are similar to the injection formulation (30).”
BackgroundHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416 · cited 2×
“A number of studies have evaluated the cost effectiveness of GLP-1RAs in the treatment of diabetes, and the efficiency parameter is mostly HbA1c, but only a few studies have evaluated their weight-loss efficacy (15).”
BackgroundWysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · cited 1×
“21037/atm-22-200 efficiency data were obtained from randomized, placebocontrolled clinical trials (18-21).”
Xu, H., Cupples, L. A., Stokes, A., & Liu, C.-T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.4587 · Cited by 182 · cited 1×
“In the United States (US), overweight or obesity rates have increased threefold in the last 40 years (2).”
Background
Cited by
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“In short term analyses ( ∼ 1/2 year) evaluating quality adjusted life years (QALYs) and incremental cost effectiveness ratios (ICERs), semaglutide was the most cost-effective compared to exenatide, dulaglutide, liraglutide or no treatment 82 (Fig.”
BackgroundThe psychophysiology of anxiety.
LADER, M. H. (1983) · PubMed · Cited by 133
Semaglutide vs endoscopic sleeve gastroplasty for weight loss
Haseeb, M., Chhatwal, J., Xiao, J., Jirapinyo, P., & Thompson, C. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6221 · Cited by 73
Cohen, R. V., Busetto, L., Levinson, R., Le Roux, C. W., Salminen, P., Prager, G., Surgery, I. C. O. T. R. O. O. M. M. I. T. C. O. M. B., Aminian, A., Blüher, M., Carlsson, L., et al. (2024) · British Journal of Surgery · doi:10.1093/bjs/znae283 · Cited by 52
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14940 · Cited by 40
“A recent study attempted to calculate quality-adjusted life years indirectly for glucagon-like peptide-1 agonists based on existing data and found that semaglutide was the most costeffective of the drugs tested.(16) Tirzepatide is first in a new drug class that also induces clinically relevant weight reduction.”
BackgroundCost-effectiveness analysis of five anti-obesity medications from a US payer's perspective
Gómez Lumbreras, A., Tan, M. S., Villa-Zapata, L., Ilham, S., Earl, J. C., & Malone, D. C. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.012 · Cited by 34
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“Patients who could benefit the most from these drugs may not be able to afford them [184,193].”
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
“However, compared to endoscopic sleeve gastroplasty, semaglutide is less cost-effective over 5 years with the same outcome parameters and a current annual price of approximately $13,618 in the US [144, 145].”
Jackson, S. E., Brown, J., Llewellyn, C. H., Mytton, O. T., & Shahab, L. (2026) · BMC Medicine · doi:10.1186/s12916-025-04528-7 · Cited by 48
“While GLP-1 and GLP-1/GIP medications are generally considered cost-effective for treating obesity in targeted populations [65–67], alternative strategies—such as expanding bariatric surgery access, enhancing lifestyle intervention programmes, pharmaceutical management of cardiometabolic…”
Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Obesity · doi:10.1002/oby.23752 · Cited by 27
“However, this study evaluated only submaximal doses [16].”
BackgroundWang, W., Wei, R., Huang, Z., Luo, J., Pan, Q., & Guo, L. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3680 · Cited by 23
“5 mg once per week), or exenatide (10μg, twice per day), semaglutide provided a cost‐effective strategy with an incremental cost‐effectiveness ratio of $135,467/quality‐adjusted life years (QALY).(41) The use of GLP‐1 agonists to reverse prediabetes with overweight/obesity may be economically feasible and sustainable.”
Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.5.441 · Cited by 32
McGowan, B. M., Houshmand‐Oeregaard, A. S., Laursen, P. N., Zeuthen, N., & Baker‐Knight, J. (2023) · Obesity · doi:10.1002/oby.23732 · Cited by 21
“In a study comparing the cost-effectiveness of GLP-1 receptor agonists for the treatment of obesity, semaglutide was found to be more cost-effective than liraglutide, dulaglutide, and exenatide in a US setting [24].”
BackgroundPatoulias, D., Koufakis, T., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s471476 · Cited by 19
“40 Similar results were obtained from other relevant analyses, 42,43 which demonstrated that liraglutide is substantially less cost-effective versus semaglu-tide for the therapeutic management of obesity.”
MethodResultInfluentialMousavi, A., Shojaei, S., Azarboo, A., Bahri, R. A., Mohammadi, S., Alilou, S., Yousefifar, S., Maleki, S., & Radkhah, H. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01770-z · Cited by 14
“Despite the potential benefits of GLP-1RAs, several challenges hinder their implementation in managing WR after bariatric surgery [15, 16].”
Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease
Rennert‐May, E., Manns, B., Clement, F. M., Spackman, E., Collister, D., Sumner, G., Leal, J. R., Miller, R. J. H., & Chew, D. S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.09.025 · Cited by 22
Dhippayom, T., Meraz, M., Lee, H., Hur, C., Inadomi, J. M., Veettil, S. K., Dunn, J. D., & Chaiyakunapruk, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70322 · Cited by 14
Martikainen, J. A., Lehtimäki, A.-V., Jalkanen, K., Lavikainen, P., Paajanen, T. I., Marjonen, H., Kristiansson, K., Lindström, J., & Perola, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.880799 · Cited by 12
“Therefore, for example, recently published studies have not considered the impacts of adverse effects of liraglutide (Shah et al., 2018; Lee et al., 2020; Hu et al., 2022).”
BackgroundLee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
Fu, W., Lin, J., You, C., Zhang, J., Lei, J., Zheng, L., Zheng, B., Liu, M., Liu, L., & Li, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16581 · Cited by 8
“Compared to other models, 13,43 – 45 the model used in this study excluded chronic conditions such as sleep apnoea syndrome, cancer, or chronic kidney disease.”
Jacobson, S., Margolese, N., & Margolese, H. C. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251386626 · Cited by 11
“27 This result was largely driven by semaglutide ’ s superior weight-loss ef fi cacy and modelled real-world utility.”
Lu, X., & Zhongyou, S. (2023) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174423000466 · Cited by 6
Jackson, S. E., Brown, J., Llewellyn, C. H., Mytton, O. T., & Shahab, L. (2025) · medRxiv · doi:10.1101/2025.06.06.25329114 · Cited by 5
Cozma, D. C., Văcărescu, C., & Stoicescu, C. I. (2025) · Biomedicines · doi:10.3390/biomedicines13123079 · Cited by 6
“…GLP-1Ras target vascular, metabolic, and neuroprotective pathways, whereas fasting activates cellular stress responses, autophagy, mitochondrial biogenesis, and nutrient-sensing pathways (AMPK, sirtuins, mTOR), offering convergent pathways toward improved health span and longevity [38,41,46].”
Taha, M. B., Javed, Z., Nwana, N., Acquah, I., Satish, P., Sharma, G. V., Sabouret, P. F., Cainzos‐Achirica, M., & Nasir, K. (2023) · Population Health Management · doi:10.1089/pop.2022.0280 · Cited by 6
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies
Pietroluongo, E., Pannain, S., Garassino, M. C., & Bestvina, C. M. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.03.002 · Cited by 4
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
Seetharaman, R., Monteiro, R. C., Maradia, J., & Tripathi, R. K. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0058 · Cited by 4
Cost-Effectiveness Analysis of Endoscopic Sleeve Gastroplasty
Daniel, M., Fritz, C. D. L., Abebe, T. B., Bazarbashi, A. N., Sullivan, S. A., Chang, S., & Kushnir, V. M. (2024) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2024.06.001 · Cited by 3
The Real-World Costs of GLP-1 Receptor Agonist TreatmentPreprint
Wennberg, D. E., Coetzer, H., Marr, A. L., Margiotta, C., Hashmi, R., Kay, J., Vats, V., Hagen, S., Anatale‐Tardiff, L., Rao, S., et al. (2025) · medRxiv · doi:10.1101/2025.10.24.25338255 · Cited by 8
Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review
Afshari, S., Khosravi, M., Zamandi, M., Rezapour, A., Hadian, M., Souresrafil, A., Mazaheri, E., & Gallehzan, N. A. (2025) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_368_24 · Cited by 5
“[35] SEMA 2.4 mg is a glucagon‑like peptide‑1 (GLP‑1) analog that aids in weight loss through mechanisms such as increasing satiety, enhancing satisfaction from food, and reducing hunger.”
InfluentialBawazeer, N., Ganzal, S. B., Al-Hasinah, H. F., & AlRuthia, Y. S. (2025) · Healthcare · doi:10.3390/healthcare13141755 · Cited by 1
“Further analyses have indicated that among the four evaluated GLP-1 RAs, Semaglu-tide presents a cost-effective strategy, with an incremental cost-effectiveness ratio (ICER) of USD 135,467 per QALY based on a WTP threshold of USD 195,000 per QALY [18].”
InfluentialA comprehensive economic assessment of the burden of obesity in Kuwait
Nagi, M. A., Ahmed, H., Almari, M., Almalki, Z. S., & Elradi, Y. M. Z. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344040 · Cited by 2
“Current evidence demonstrates that GLP-1 receptor agonists are both effective and cost-effective, not only in promoting weight reduction but also in improving metabolic parameters, thereby mitigating complications associated with obesity [69,70].”
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Reframing the need for exercise therapy in the clinical management of people living with obesity
Grannell, A. (2022) · Clinical Obesity · doi:10.1111/cob.12554 · Cited by 1
“Evidence for the cost effectiveness of novel GLP-1 anti-obesity medications has been described in the literature.(31) Primary care providers are well positioned to diagnose and treat obesity (Fitch and Ingersoll 2020).”
BackgroundDirect Monetary Cost of Obesity in Patients: A Study from a Health Economics PerspectivePreprint
Eren, F. A., & Boz, C. (2023) · Research Square · doi:10.21203/rs.3.rs-3319952/v1
Spence, D. B., Austin, R. P., Carrol, C., Pierce, S., Richter, D. L., Chamberlain, R., & Schenck, R. C. (2024) · JBJS Journal of Orthopaedics for Physician Assistants · doi:10.2106/jbjs.jopa.24.00005 · Cited by 2
Carrasquel, C. M., Suzuki, É. H. K., Costa, R. V. S., Cota, R. B., & Dantas, R. A. E. (2024) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e15334.2024
Fu, W., Zheng, Z., Lin, J., You, C., Zhang, J., Lei, J., Zheng, L., Zheng, B., Liu, M., & Li, N. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5378169
INNOVATIONS IN OBESITY TREATMENT – GLP – 1 PHARMACOTHERAPY AND BARIATRIC SURGERY
Bartnik, P., Palmi, J., Bebrysz, E., Dębek-Kalinowska, K., Baran, J., Dunder, I., Koss, M., Biszewski, M., Drabik, A., & Ziomek, W. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3682
Farley, B., Radetich, E., D’Alessandro, J. S., & Bulaj, G. W. (2025) · Healthcare · doi:10.3390/healthcare13243220 · Cited by 2
“While GLP1RAs, such as semaglutide, dulaglutide, and tirzepatide, are effective in the reduction in A1c and weight, they do not always demonstrate cost-effectiveness [22,23].”
Malone, S. K., Glenn, A. J., Paulhamus, D. R., & Patterson, F. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105902
Sibal, R., Balamurugan, G., Aradaib, M., Graham, Y. N. H., & Mahawar, K. K. (2026) · Medicina · doi:10.3390/medicina62101916
“…recent obesity guidelines [55–57] Cost-effectiveness Uncertain due to limited durability and potential need for repeat interventions [28,58] Increasing evidence of cost-effectiveness with sustained use and cardiometabolic benefit [59,60] IGBs generally achieve approximately 10–15% TBWL at 6 months.”
Tauseef, U., Farook, F., Shetty, V. J., Ramos-Ocola, E., Premkumar, C. R., Haider, M., Gandhi, A., Shingala, T. S., Singh, S., TAHIR, M. M., et al. (2026) · Reproductive Medicine · doi:10.3390/reprodmed7040055
Metadata
- Authors
- Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P.
- Affiliations
- Zhejiang Provincial People's Hospital (CN)
- Corresponding author
- Huang, Ping
- ORCID
- Huang, Ping
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2022-02
- Volume
- 10
- Issue
- 3
- Pages
- 152-152
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- PMC
- PMC8904982
- OpenAlex
- W4212785398
- Semantic Scholar
- bbfa8cf3066ae7519753db8df3c2cc1fd8ba6ed2
- Cited by
- 45
- References
- 35
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 9 · 2023: 7 · 2022: 3
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82003189)
- Zhejiang Pharmaceutical Association
- Natural Science Foundation of Zhejiang Province (LQ17H310002, No. LQ17H310002, LYY19H310009, LYY21H310011)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- obesity, GLP-1 receptor agonists, anti-obesity drugs, cost-effectiveness, semaglutide, liraglutide, dulaglutide, exenatide, quality-adjusted life years, incremental cost-effectiveness ratio, willingness-to-pay threshold, decision tree
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.